학술논문

PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies
Document Type
article
Source
Pancreas. 47(10)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Pancreatic Cancer
Prevention
Digestive Diseases
Rare Diseases
Cancer
Clinical Research
2.1 Biological and endogenous factors
4.2 Evaluation of markers and technologies
Detection
screening and diagnosis
Aetiology
Oral and gastrointestinal
Adult
Biomarkers
Blood Specimen Collection
Diabetes Mellitus
Disease Progression
Humans
Longitudinal Studies
Observational Studies as Topic
Outcome Assessment
Health Care
Pancreatic Neoplasms
Pancreatitis
Chronic
Prospective Studies
Research Design
Specimen Handling
Translational Research
Biomedical
United States
pancreas
alcohol
tobacco
genetic
biorepository
cohort
Consortium for the Study of Chronic Pancreatitis
Diabetes
and Pancreatic Cancer
Gastroenterology & Hepatology
Clinical sciences
Language
Abstract
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.